CN114569727B - 一种治疗癌症的组合物及其应用和药物 - Google Patents
一种治疗癌症的组合物及其应用和药物 Download PDFInfo
- Publication number
- CN114569727B CN114569727B CN202011383945.8A CN202011383945A CN114569727B CN 114569727 B CN114569727 B CN 114569727B CN 202011383945 A CN202011383945 A CN 202011383945A CN 114569727 B CN114569727 B CN 114569727B
- Authority
- CN
- China
- Prior art keywords
- her2
- cancer
- sglt1
- inhibitor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 62
- 201000011510 cancer Diseases 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 20
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 108091006277 SLC5A1 Proteins 0.000 abstract description 103
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract description 101
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract description 101
- 239000003112 inhibitor Substances 0.000 abstract description 51
- 229940125497 HER2 kinase inhibitor Drugs 0.000 abstract description 34
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 abstract description 11
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000003993 interaction Effects 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 abstract 3
- 102100020885 Sodium/glucose cotransporter 1 Human genes 0.000 description 100
- 210000004027 cell Anatomy 0.000 description 65
- 230000014509 gene expression Effects 0.000 description 26
- 206010061535 Ovarian neoplasm Diseases 0.000 description 24
- 206010033128 Ovarian cancer Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 108091006269 SLC5A2 Proteins 0.000 description 13
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 108091027967 Small hairpin RNA Proteins 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 238000003197 gene knockdown Methods 0.000 description 9
- 238000010837 poor prognosis Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 5
- 239000012083 RIPA buffer Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229960004891 lapatinib Drugs 0.000 description 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 229960000575 trastuzumab Drugs 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229940126902 Phlorizin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000749 co-immunoprecipitation Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 3
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 3
- 235000019139 phlorizin Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- XFJAMQQAAMJFGB-ZQGJOIPISA-N (2s,3r,4r,5s,6r)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=C(CC=2C=C3OCCOC3=CC=2)C(CC)=CC=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XFJAMQQAAMJFGB-ZQGJOIPISA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 2
- 230000006536 aerobic glycolysis Effects 0.000 description 2
- 229960003982 apatinib Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229950007440 icotinib Drugs 0.000 description 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 229960003784 lenvatinib Drugs 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 229940121293 licogliflozin Drugs 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940071104 xylenesulfonate Drugs 0.000 description 2
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 1
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000034534 Cotransporters Human genes 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710103121 Sodium/glucose cotransporter 1 Proteins 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 101150042537 dld1 gene Proteins 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950005268 sotagliflozin Drugs 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及医药技术领域，具体公开了一种治疗癌症的组合物及其应用和药物。本发明所述组合物包括SGLT1抑制剂和HER2抑制剂。本发明发现SGLT1与HER2具有相互作用并促进肿瘤的发生发展；同时，靶向HER2的抑制剂与SGLT1抑制剂的组合物具有协同抗肿瘤效应，可将靶向HER2和SGLT1的抑制剂组合物用于癌症治疗和抗癌药物的制备中。
Description
技术领域
本发明涉及医药技术领域，更具体的说是涉及一种治疗癌症的组合物及其应用和药物。
背景技术
早在19世纪80年代，科学家就发现HER2蛋白具有将正常成纤维细胞转化为癌细胞的能力，并定义HER2为原癌基因(Shih C,Padhy LC,Murray M, WeinbergRA.Transforming genes of carcinomas and neuroblastomas introduced into mousefibroblasts.Nature 1981；290:261–264.)。此后大量的临床实验数据表明大约25-30％的乳腺癌和卵巢癌中存在HER2的基因扩增和蛋白过表达。例如乳腺癌可以有多达25-50个HER2基因拷贝数以及40-100倍的HER2蛋白增量最终在肿瘤细胞表面形成200万个HER2受体，远远高于正常的乳腺导管上皮细胞(Venter DJ,Tuzi NL,Kumar S,GullickWJ.Overexpression of the c-erbB-2oncoprotein in human breast carcinomas:immunohistological assessment correlates with gene amplification.Lancet 1987；2:69–72)。除基因扩增导致的HER2蛋白表达量上调外，近年来研究发现HER2酶活性组成激活型突变也在多种癌症中出现。高突变率(>10％)的癌种包括前列腺神经内分泌癌、转移性皮肤鳞状细胞癌和膀胱尿路上皮癌。此外，HER2突变也出现在常见的癌症如肺癌、结直肠癌和乳腺癌中(Connell CM,Doherty GJ.Activating HER2 mutations as emergingtargets in multiple solid cancers.ESMO Open. 2017；2[5]:e000279.)，而且HER2的基因扩增以及组成型酶活性突变通常与肿瘤的不良预后相关。随后的大量研究表明HER2的扩增以及激活型突变是肿瘤细胞生长所依赖的，敲低HER2会抑制肿瘤细胞生长并引起肿瘤细胞死亡 (Faltus T,Yuan J,Zimmer B,Kramer A,Loibl S,Kaufmann et al..Silencingof the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis inHER2/neuoverexpressing breast cancer cells.Neoplasia 2004；6:786–795.)。以上这些研究表明HER2是一个良好的肿瘤治疗靶点。因而围绕HER2这一靶点开发出了以曲妥珠单抗为代表的单抗类HER2抑制剂以及近年来开发的拉帕替尼，来那替尼，涂卡替尼等小分子抑制剂以及基于曲妥珠单抗的抗体偶联药物。这些药物的单独使用以及与经典化疗药物的联用显著改善了HER2阳性癌症的治疗结局(Baselga J,Cortes J,Kim SB,Im SA,Hegg R,Im YH,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breastcancer.N Engl J Med.2012；366[2]:109-19)。然而与其他靶向药在治疗癌症中所出现的问题一致，HER2单抗以及TKI类药物通常会出现耐药性，如何克服耐药性增强靶向药的杀伤性成为亟需解决的问题。
肿瘤细胞不同于正常细胞的一个标志为癌细胞即便在氧气充足的条件下也优先使用有氧糖酵解来为肿瘤细胞提供能量。有氧糖酵解相比于氧化磷酸化产能效率低很多，这就需要肿瘤细胞转运葡萄糖的能力显著增强(Hanahan D et al,Hallmarks of cancer:the next generation,Cell,144(5):646-674(2011)，这通过过表达质膜转运蛋白来实现(Ganapathy V,et al,Nutrient transporters in cancer:relevance to Warburghypothesis and beyond,Pharmacology&Therapeutics 121(1):29-40(2009)。葡萄糖共转运蛋白1(SGLT1)为主动的葡萄糖转运蛋白，其依靠细胞外钠浓度将葡萄糖转运至细胞而不依赖于葡萄糖浓度(Wright EM,et al,Biology of human sodium glucosetransporters,Physiological Reviews,91(2):733-794(2011))。研究表明SGLT1在多种癌症中高表达且与癌症的不良预后相关，所述癌症包括乳腺癌、卵巢癌、口腔鳞状细胞癌、结直肠癌、胰腺癌和前列腺癌。SGLT1可以结合并稳定EGFR从而促进肿瘤细胞的生长，增殖，将根皮苷类SGLT1抑制剂pholorizin与EGFR抑制剂吉非替尼等联用可以使吉非替尼耐药细胞株再次对吉非替尼敏感(J,Vrhovac/>I,Gajski G,/>J,GarajVrhovacV.Apigenin:A dietary flavonoid with diverse anticancer properties.Cancer Lett2018；413:11-22.Koepsell H.The Na+ -D-glucose cotransporters SGLT1 and SGLT2are targets for the treatment of diabetes and cancer.Pharmacol Ther 2017；170:148–65.Yamazaki Y,Harada S, Tokuyama S.Sodium–glucose transporter as a noveltherapeutic target in disease. Eur J of Pharmacol 2018；822:25–31)。因而SGLT1抑制剂具有逆转与之相互作用的EGFR抑制剂耐药性的能力。
目前，还未见将SGLT1抑制剂与小分子抑制剂以及单抗类药物组合使用用于解决本领域治疗耐受HER2酪氨酸激酶抑制剂的癌症的报道。
发明内容
有鉴于此，本发明的目的在于提供一种治疗癌症的组合物，使得所述组合物中的HER2抑制剂与SGLT1抑制剂具有协同抗肿瘤效应；
本发明的另外一个目的在于提供上述组合物在制备治疗癌症药物中的应用；
本发明的另外一个目的在于提供包含上述组合物的治疗癌症的药物；
为实现上述发明目的，本发明提供如下技术方案：
一种治疗癌症的组合物，包括SGLT1抑制剂和HER2抑制剂。
本发明发现SGLT1与HER2具有相互作用并促进肿瘤的发生发展，且这种相互作用对彼此的功能发挥具有重要作用，敲低HER2不但会影响肿瘤细胞的增殖以及生长信号的转到同时也会影响SGLT1功能，反之敲低SGLT1 不但影响癌细胞在低糖条件下的生存也会影响HER2信号通路以及细胞的增殖，因此本发明由此预期两者的抑制剂联合使用将会产生协同抗肿瘤的作用；经过实验验证，HER2抑制剂以及SGLT1抑制剂组成的组合物对肿瘤生长具有显著抑制作用，该组合物对肿瘤的抑制具有显著的协同增效作用。
因此，本发明提供上述组合物在制备治疗癌症药物中的应用；所述癌症包括但不限于膀胱癌、血癌、骨癌、脑癌、乳腺癌、中枢神经系统癌症、宫颈癌、结肠癌、子宫内膜癌、食管癌、胆囊癌、胃肠道癌、外生殖器癌、泌尿生殖道癌、头癌、肾癌、喉癌、肝癌、肺癌、肌肉组织癌症、颈癌、口腔或鼻黏膜癌、卵巢癌、胰腺癌、前列腺癌、皮肤癌、脾癌、小肠癌、大肠癌、胃癌、睾丸癌和甲状腺癌。
作为优选，所述组合物中0＜SGLT1抑制剂浓度为≤100μM，所述组合物中0＜HER2抑制剂浓度≤100μM。在本发明具体实施方式中，所述SGLT1抑制剂浓度为5、10、20、30、40或60μM，所述HER2抑制剂浓度为0.1、 2.5、5、10、20、40、50、60、80或100μM。
在本发明具体实施方式中，所述SGLT1抑制剂选自索格列净、SY-009 (购自亚宝药业)、Licogliflozin(购自诺华制药)中的一种或两种以上；所述HER2抑制剂选自拉帕替尼、来那替尼、沙普替尼、波齐替尼、图卡替尼、二甲苯磺酸拉帕替尼以及靶向HER2的单抗中的一种或两种以上。其中，靶向HER2的单抗如曲妥珠单抗，但并不限于此，本领域技术人员认为可行的靶向HER2的单抗均在本发明保护范围之内。
根据本发明所提供的应用，本发明还提供了一种治疗癌症的药物，其包含本发明所述组合物以及药学上可接受的助剂。
作为优选，药物剂型为口服药物的各种剂型，包括但不限于颗粒剂、丸剂、散剂、片剂、胶囊剂、口服液、糖浆剂等形式。
由以上技术方案可知，本发明发现SGLT1与HER2具有相互作用并促进肿瘤的发生发展；同时，靶向HER2的抑制剂与SGLT1抑制剂的组合物具有协同抗肿瘤效应，可将靶向HER2和SGLT1的抑制剂组合物用于癌症治疗和抗癌药物的制备中。
附图说明
图1所示为HER2(即图中ERBB2)与SGLT1高表达与乳腺癌、卵巢癌患者不良预后相关结果；其中，1A为HER2高表达与乳腺癌患者预后的关系， 1B为HER2高表达与卵巢癌患者预后关系，1C为SGLT1高表达与乳腺癌患者预后的关系，1D为SGLT1高表达与卵巢癌患者预后关系；
图2所示HER2(即图中ERBB2)与SGLT1(即图中SLC5A1)、SGLT2 (即图中SLC5A2)在乳腺癌和卵巢癌中具有正相关性得结果；其中，2A为 HER2与SGLT1在乳腺癌中的表达具有正相关性，2B为HER2与SGLT1在卵巢癌中的表达具有正相关性；2C为HER2与SGLT2在乳腺癌中的表达具有正相关性，2D为HER2与SGLT2在卵巢癌中的表达具有正相关性；
图3所示卵巢癌细胞系中敲除/过表达SGLT1后对HER2蛋白的水平影响；敲除SGLT1后对HER2蛋白的水平随之下降，过表达SGLT1后HER2 蛋白的水平随之增加；3A为敲除SGLT1和SGLT2后检测HER2蛋白的水平， 3B为SGLT1敲除效果检测，3C为过表达SGLT1增加HER2蛋白水平；其中， C是正常对照组，S1是敲低SGLT1，S2是敲低SGLT2，H1和H2是敲低 HER2，MG132为阳性对照；
图4所示为SGLT1对HER2蛋白稳定性的影响结果；4A为敲低SGLT1 损伤HER2蛋白的稳定性，4B为过表达SGLT1后HER2的蛋白稳定性增加；其中，此试验以蛋白合成抑制剂放线菌酮处理不同时长(0、2、4、8h)的细胞的HER2蛋白水平变化来显示HER2蛋白的稳定性；
图5所示为敲低HER2对细胞摄取葡萄糖的影响结果；其中，C表示正常对照组，H1表示敲低HER2组；
图6所示HER2和SGLT1抑制剂单用以及联用对HER2信号通路的影响；其中，C为正常对照，T为HER2抑制剂图卡替尼缩写，S为SGLT1抑制剂索格列净的缩写，TS是两种抑制剂联用；
图7所示HER2与SGLT1的免疫印迹试验结果；
图8-14所示HER2抑制剂图卡替尼以及SGLT1抑制剂索格列净对多种癌细胞系的影响；图8示HER2抑制剂以及SGLT1抑制剂处理胃癌细胞系 HGC27；图9示HER2抑制剂以及SGLT1抑制剂处理宫颈癌细胞系HeLa；图10示HER2抑制剂以及SGLT1抑制剂处理乳腺癌细胞系MCF-7；图11 示HER2抑制剂以及SGLT1抑制剂处理肝癌细胞系QGY-7703；图12示 HER2抑制剂以及SGLT1抑制剂处理前列腺癌细胞系DU145；图13示 HER2抑制剂以及SGLT1抑制剂处理结食管癌细胞系KYSE30；图14示 HER2抑制剂以及SGLT1抑制剂处理胆管癌细胞系RBE；其中，S表示索格列净，各图中等号后面所列数值为索格列净的浓度μM；
图15-16所示为HER2抑制剂图卡替尼以及多种SGLT1抑制剂对肿瘤结直肠癌细胞系SW620的影响；其中，S表示索格列净、target3表示Licogliflozin (诺华制药)、target5表示SY-009(亚宝药业)，各图等号后的数值为对应 SGLT1抑制剂的浓度μM；
图17所示为多种HER2抑制剂以及SGLT1抑制剂索格列净处理高表达 HER2的卵巢癌细胞系SKOV3的结果；10-1至10-5别示拉帕替尼(10-1)、来那替尼(10-2)、沙普替尼(10-3)、波齐替尼(10-4)、二甲苯磺酸拉帕替尼(10-5)与SGLT1抑制剂索格列净联用的肿瘤抑制效果；其中，S表示索格列净，各图中等号后面所列数值为索格列净的浓度μM，浓度为0的柱型表示HER2抑制剂以及SGLT1抑制剂索格列净的浓度皆为0。
具体实施方式
本发明公开了一种治疗癌症的组合物及其应用和药物，本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明所述组合物及其应用和药物已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述组合物及其应用和药物进行改动或适当变更与组合，来实现和应用本发明技术。
本发明经TCGA数据分析恶性肿瘤的不良预后与表皮生长因子受体 2(HER2)以及钠/葡萄糖共转运蛋白1(SGLT1)的过表达相关。所述癌症包括乳腺癌、卵巢癌等多种癌症。
本发明发现SGLT1与HER2具有相互作用，且这种相互作用对彼此的功能发挥具有重要作用，敲低HER2不但会影响肿瘤细胞的增殖以及生长信号的转到同时也会影响SGLT1功能，反之敲低SGLT1不但影响癌细胞在低糖条件下的生存也会影响HER2信号通路以及细胞的增殖。因此，HER2抑制剂以及SGLT1抑制剂组成的组合物对肿瘤生长具有显著抑制作用，该组合物对肿瘤的抑制具有显著的协同增效作用。
在本发明具体实施方式中，进行了如下方面的试验验证：
(1)在卵巢和乳腺癌中HER2、SGLT1、SGLT2的高表达对癌症患者的不良预后的影响；
(2)SGLT1对HER2信号通路的作用；
(3)HER2对SGLT1功能正常发挥的作用；
(4)HER2与SGLT1之间的相互作用；
(5)HER2与SGLT1抑制剂单药以及组合物对肿瘤细胞的作用；
上述试验中所涉及的实验操作和方法可参照如下：
1、细胞和试剂
本发明所用肝癌细胞系QGY7703；结直肠癌细胞系SW620、HCT116、 SW480、LOVO、HT29、DLD1；宫颈癌HeLa；卵巢癌SKOV3；胃癌NGC27；胆管癌RBE；食管癌KYSE30以及HEK293T细胞系均从美国典型培养物保藏中心(ATCC)并在含有5％CO2的37℃孵箱中培养，所述细胞系的维持培养基为补充有10％胎牛血清(Gibico)和1％青霉素/链霉素(Gibico)的DMEM 或者RPMI 1640(Gibico)中。小鼠抗Flag标签抗体(F3165)，Flag抗体欧联M2 微珠购自Sigma-Aldrich(St.Louis,MO)，兔GAPDH内参抗体以及辣根过氧化物酶标记的抗兔和小鼠二抗购自博奥龙公司。Sotagliflozin、阿帕替尼和乐伐替尼均获自Selleckchem(Houston,TX)。抗pERK的抗体(4370)获自Cell Signaling(Danvers,MA)。MTT试剂盒(目录号30-1010K)获自ATCC。
2、质粒构建
将人野生型HER2克隆至pCMV-tag2B载体，人野生型SGLT1序列克隆至pEGFP-N1载体中。将靶向如下Sglt1-1 shRNA序列:5’- AGGAGAGCCTATGACCTATTT-3’；Sglt1-2 shRNA序列:5’-GCCTGATG CTATCAGTCATGC-3’；Sglt2-1 shRNA序列:5’-GCATATTTCCTGC TGGTCATT-3’；Sglt2-2 shRNA序列:5’ -GGTCATCACGATGCCACAGTA-3’；HER2-1 shRNA序列:5’ -GATGAAAGTTACCAGTCTATT-3’；HER2-2 shRNA序列:5’ -GCTGACATGTACGGTCTATGC-3’序列的shRNA构建到 pLVX-shRNA2-puro载体用于后续包被慢病毒构建SGLT1、SGLT2、HER2敲低的细胞系。所有载体通过测序验证为正确质粒。
3、瞬时转染和免疫共沉淀
用表达Flag标记的SGLT1的质粒单独转染或与指定的GFP标记的 HER2载体在无血清DMEM培养基中混合并加入转染试剂PEI后一起转染 HEK293T细胞。在转染6小时之后更换为10％血清的培养基，更换培养基之后24小时，弃去培养基，用10毫升1×磷酸盐缓冲液中洗涤(PBS)将细胞吹起并1500转离心，弃去上清所得细胞团沉淀加入补充有蛋白酶抑制剂混合物的RIPA缓冲液(50mM Tris-HCl，pH 8.0，具有150mM氯化钠，1.0％Igepal CA-630(NP-40)，0.5％脱氧胆酸钠和0.1％十二烷基硫酸钠)并在摇床于4℃下裂解30分钟。然后，将细胞裂解物以12000×rpm离心10分钟。将上清液加入偶联有Flag抗体的M2微珠于4℃孵育过夜。然后，将样品离心，用RIPA 缓冲液洗涤三次，在Laemmle缓冲液(Biorad,CA)中煮沸，用8％SDS PAGE 胶进行蛋白质印记分析。
4、蛋白质印记分析
对于蛋白质印记(Western blot)分析，将细胞用恰当体积的RIPA缓冲液 (150mMNaCl，50mM Tris-HCl，pH 7.4，0.1％SDS，1％TritonX-100，1mM EDTA，1mM PMSF，1％脱氧胆酸钠，1mM NaF，1mM Na3VO4，于去离子水中)在4℃条件下或者冰上裂解30分钟以上。12000×rpm离心10分钟，上清用BCA试剂盒(Thermo)测定蛋白浓度后加入5×loading Buffer在100℃煮沸10分钟。短暂离心后，将样品通过10％SDS-PAGE进行电泳分离后转移至PVDF膜，随后用5％脱脂奶粉封闭一小时以上，然后在4℃下与一抗在最佳浓度过夜孵育。将膜用0.1％PBST(1×TBS，0.1％吐温-20)洗涤3次，每次10分钟，然后与二抗在室温孵育1小时。通过增强化学发光使信号可视化。
5、细胞生长测定
根据生产厂家提供的方案，检测原理为活细胞线粒体中的琥珀酸脱氢酶能使外源性MTT还原为水不溶性的蓝紫色结晶甲臜(Formazan)并沉积在细胞中，而死细胞无此功能。二甲基亚砜(DMSO)能溶解细胞中的甲臜，用酶联免疫检测仪在570nm波长处测定其光吸收值，可间接反映活细胞数量。在96 孔板中通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)测定来确定细胞生长。具体而言，细胞消化计数，将细胞重悬浮成每200μL培养基含5000 个细胞的体系，接种在在96孔板的每个孔中。第二天，将培养基用含有不同浓度的索格列净，HER2抑制剂以及它们之间的组合物的培养基更换。在与药物孵育48或72小时之后，将20μL MTT试剂加入至每个孔中并孵育2小时。在弃去培养基之后，将细胞中的甲臜沉淀物溶解在100μL DMSO中。通过酶标仪在570nm下测量吸光度。在每组中使用一式四份样品。
7、统计分析
将学生t检验用于评估索格列净，阿帕替尼，乐伐替尼等SGLT1和HER2 抑制剂不同浓度，不同组合条件处理下的细胞的生长差异以及裸鼠移植瘤生长差异。P值小于0.05被定义为具有统计显著性。
本发明提供的治疗癌症的组合物及其应用和药物中所用试剂或仪器均可由市场购得；所进行对比实验除去应有的区别外，如无特殊说明其他实验条件保持一致，以便具有可对比性。
下面结合实施例，进一步阐述本发明。
实施例1：HER2和SGLT1高表达正相关且与癌症患者不良预后相关
图1中，1A和1B通过对TCGA数据库分析卵巢癌、乳腺癌患者癌组织中的 HER2表达高低与患者总生存期的关联性得出HER2高表达的患者总生存期更短；1C,1D通过对TCGA数据库分析卵巢癌、乳腺癌癌患者癌组织中的SGLT1 表达高低与患者总生存期的关联性得出SGLT1高表达的患者总生存期更短；证明HER2以及SGLT1的高表达与这两种癌症患者的不良预后相关，说明二者在肿瘤细胞自身的表达中与预后的关系。
本实施例通过挖掘TCGA数据库将HER2以及SGLT1、SGLT2的表达量与卵巢癌和结直肠癌患者的总生存期进行生存分析发现，HER2以及SGLT1的高表达与卵巢癌、乳腺癌患者的不良预后正相关。
本实施例仅以举例方式证明HER2以及SGLT1的高表达与这两种癌症患者的不良预后相关，说明二者在肿瘤细胞自身的表达中与预后的关系。这并不能限制为本发明实施方案的组合物仅限于卵巢癌和结直肠癌。在本发明其他实施方案中组合物即对宫颈癌，前列腺癌，肝癌，结直肠癌，胃癌，食管癌，胆管癌细胞系等多种癌症具有显著抑制作用，如图8，图9所示。
此外，本发明还通过皮尔森检验对从TCGA数据库中获得的HER2和 SGLT1、SGLT2在卵巢癌和乳腺癌患者中的表达量数据进行关联性分析发现 HER2与SGLT1的表达之间存在正相关性，而与SGLT2之间的表达量无相关性，如图2A、2B、2C、2D所示。这说明HER2与SGLT1两者功能具有一定关联性。
实施例2：HER2与SGLT1对彼此功能相互影响
利用shRNA技术从卵巢癌细胞系SKOV3中敲低SGLT1、SGLT2以及 HER2后和利用外源载体过表达SGLT1后，图3Western检测结果显示， 3A,3C说明敲低SGLT1，HER2的蛋白水平随之降低，过表达SGLT1，HER2 的蛋白水平随之升高；但是，敲低SGLT2，HER2的蛋白水平并未产生变化。说明SGLT1影响HER2蛋白的功能，但是SGLT2不影响HER2蛋白的功能；
此外，利用蛋白翻译抑制剂放线菌酮抑制蛋白翻译观察蛋白半衰期的办法，评价敲低或者过表达SGLT1是否会相应缩短或延长HER2半衰期。利用 shRNA技术从卵巢癌细胞系SKOV3中敲低SGLT1以及利用外源载体过表达SGLT1后，在细胞培养液中加入蛋白翻译抑制剂放线菌酮处理后观察 HER2蛋白水平随着时间变化，结果如图4中4A和4B所示，敲低SGLT1后HER2的半衰期显著缩短，而过表达SGLT1后HER2半衰期显著延长。说明 SGLT1对HER2蛋白的稳定性至关重要，通过靶向SGLT1可以实现HER2的降解
以上结果说明SGLT1影响HER2的蛋白质稳定性。为进一步确定HER2 对SGLT1的影响，利用shRNA技术从卵巢癌细胞系SKOV3中敲低HER2后利用FITC荧光偶联的葡萄糖类似物2-BNDG处理细胞30分钟后，流式细胞仪检测FITC阳性细胞所占比例，经统计总结后结果如图5所示，敲除HER2 后细胞对2-NBDG的摄取能力显著减弱，也即敲除HER2影响了细胞对葡萄糖的摄取。这些结果表明HER2反过来也会对SGLT1的功能有一定影响，二者的功能是相互影响的。
值得提出的是，本发明仅以卵巢癌SKOV3细胞为例敲低各基因评价它们之间的相互影响，本发明所得结论不应受限于此癌种和细胞系。
实施例3：SGLT1对HER2信号通路的作用
利用HER2和SGLT1抑制剂单独或者联合处理SKOV3细胞，检测 HER2以及HER2下游分子p-ERK1/2。图6结果显示HER2以及SGLT1抑制剂联用可更好的抑制HER2信号通路激活，说明联合用药的效果优于任一靶点抑制剂的单独使用。
实施例4：HER2与SGLT1存在分子间的相互作用
本实施例通过免疫共沉淀实验进一步确定HER2与SGLT1存在分子间的相互作用。利用免疫共沉淀的方法将FLAG标签的SGLT1与HA标签的HER2载体共转染293T细胞，24小时后裂解细胞，加入FLAG珠子结合5小时，利用HA抗体和Flag抗体进行Western检测，具体方法如下：
用表达Flag标记的SGLT1的质粒单独转染或与指定的HA标记的 HER2载体在无血清DMEM培养基中混合并加入转染试剂PEI后一起转染 HEK293T细胞。在转染6小时之后更换为10％血清的培养基，更换培养基之后24小时，弃去培养基，用10毫升1×磷酸盐缓冲液中洗涤(PBS)将细胞吹起并1500转离心，弃去上清所得细胞团沉淀加入补充有蛋白酶抑制剂混合物的RIPA缓冲液(50mM Tris-HCl，pH 8.0，具有150mM氯化钠，1.0％Igepal CA-630(NP-40)，0.5％脱氧胆酸钠和0.1％十二烷基硫酸钠)并在摇床于4℃下裂解30分钟。然后，将细胞裂解物以12000×rpm离心10分钟。将上清液加入偶联有Flag抗体的M2微珠于4℃孵育过夜。然后，将样品离心，用RIPA 缓冲液洗涤三次，在Laemmle缓冲液(Biorad,CA)中煮沸，用8％SDS PAGE 胶进行蛋白质印记分析。IP＝免疫沉淀，以及Input＝在用于免疫沉淀的 HEK293全细胞裂解物中指定的外源蛋白的表达水平。结果如图7所示，HER2 与SGLT1存在蛋白之间相互作用。
实施例5：通过SGLT1抑制剂抑制SGLT1使癌细胞对HER2抑制剂敏感
图8-14仅以举例的方式说明了在肝癌细胞系QGY-7703，前列腺癌细胞系 DU145以及其他5种常见癌症细胞系中评价HER2抑制剂图卡替尼以及SGLT1 抑制剂索格列净单药以及二者不同剂量组合物联合用药HER2抑制剂图卡替尼的IC50值。结果说明，通过加入SGLT1抑制剂索格列净与HER2抑制剂图卡替尼联用，可以明显降低图卡替尼的IC50值，增加其对癌细胞的敏感性，说明两者联用存在协同作用；
同时，使用HER2抑制剂图卡替尼以及不同的SGLT1抑制剂处理结直肠癌细胞系SW620，利用MTT法分别测量HER2抑制剂以及SGLT1抑制剂单药以及二者不同剂量组合物联合用药HER2抑制剂图卡替尼的IC50值。图15-16结果显示，除索格列净外的其他SGLT1抑制剂组合物对结直肠癌细胞系同样具有协同作用且效果索格列净优于SY-009(亚宝药业)优于Licogliflozin(诺华制药) 优于根皮苷(作为对照)。
此外，利用多种HER2抑制剂以及SGLT1抑制剂处理高表达HER2的卵巢癌细胞系SKOV3，检测多种HER2抑制剂以及优选的SGLT1抑制剂索格列净二者组合物联合用药对肿瘤生长的抑制效果。图17结果证明格列净与多种HER2 抑制剂联用均能很好的发挥协同作用，组合物对肿瘤生长具有显著抑制作用，且HER2抑制剂并不局限于图卡替尼。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.一种治疗癌症的组合物，其特征在于，由索格列净和图卡替尼组成；其中：
索格列净的浓度为10μM、20μM或30μM；
0.1μM≤图卡替尼浓度≤80μM。
2.权利要求1所述组合物在制备治疗癌症药物中的应用；
所述癌症为胃癌、宫颈癌、乳腺癌、肝癌、前列腺癌、食管癌、结肠癌或胆管癌。
3.一种治疗癌症的药物，其特征在于，包含权利要求1所述组合物以及药学上可接受的助剂。
4.根据权利要求3所述药物，其特征在于，其为口服药物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311140227.1A CN117045804A (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
| CN202011383945.8A CN114569727B (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011383945.8A CN114569727B (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311140227.1A Division CN117045804A (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114569727A CN114569727A (zh) | 2022-06-03 |
| CN114569727B true CN114569727B (zh) | 2023-12-01 |
Family
ID=81766760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011383945.8A Active CN114569727B (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
| CN202311140227.1A Pending CN117045804A (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311140227.1A Pending CN117045804A (zh) | 2020-11-30 | 2020-11-30 | 一种治疗癌症的组合物及其应用和药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114569727B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132001A1 (en) * | 2012-03-07 | 2013-09-12 | Consejo Superior De Investigaciones Cientificas | Prognostic biomarkers for survival after treatment of a cancer disease with radiotherapy and/or chemotherapy |
| CN105358173A (zh) * | 2013-05-08 | 2016-02-24 | 休斯敦系统大学 | 靶向癌症治疗的egfr-sglt1相互作用 |
| CN111601613A (zh) * | 2017-12-22 | 2020-08-28 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
-
2020
- 2020-11-30 CN CN202011383945.8A patent/CN114569727B/zh active Active
- 2020-11-30 CN CN202311140227.1A patent/CN117045804A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132001A1 (en) * | 2012-03-07 | 2013-09-12 | Consejo Superior De Investigaciones Cientificas | Prognostic biomarkers for survival after treatment of a cancer disease with radiotherapy and/or chemotherapy |
| CN105358173A (zh) * | 2013-05-08 | 2016-02-24 | 休斯敦系统大学 | 靶向癌症治疗的egfr-sglt1相互作用 |
| CN111601613A (zh) * | 2017-12-22 | 2020-08-28 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
Non-Patent Citations (3)
| Title |
|---|
| SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity:Web of Science;Huiquan Liu等;Molecular Oncology;第13卷(第9期);1874-1886 * |
| SGLT1 在肝癌组织中的表达及意义;雷世雄等;现代肿瘤医学;第23卷(第3期);354-356 * |
| Sodium-glucose cotransporters: new targets of cancer therapy?;Vrhovac Madunić I等;Archives of Industrial Hygiene and Toxicology;第69卷(第4期);278-285 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114569727A (zh) | 2022-06-03 |
| CN117045804A (zh) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Menendez et al. | Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene | |
| Bollu et al. | Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation | |
| Cai et al. | The RNA-binding protein HuR confers oxaliplatin resistance of colorectal cancer by upregulating CDC6 | |
| Xu et al. | Overexpression and biological function of IQGAP3 in human pancreatic cancer | |
| Sun et al. | Overexpression of Hsc70 promotes proliferation, migration, and invasion of human glioma cells | |
| JP6309080B2 (ja) | がん治療のためのｅｇｆｒ−ｓｇｌｔ１相互作用の標的化 | |
| Xing et al. | SIRT4 enhances the sensitivity of ER‐positive breast cancer to tamoxifen by inhibiting the IL‐6/STAT3 signal pathway | |
| Park et al. | HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer | |
| Zhou et al. | Protein kinase D2 promotes the proliferation of glioma cells by regulating Golgi phosphoprotein 3 | |
| Zhong et al. | Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway | |
| Byth et al. | The cellular phenotype of AZ703, a novel selective imidazo [1, 2-a] pyridine cyclin-dependent kinase inhibitor | |
| Ding et al. | GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/β-catenin signaling pathway | |
| Bialkowska et al. | Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening | |
| Wang et al. | Bryostatin-1 inhibits cell proliferation of hepatocarcinoma and induces cell cycle arrest by activation of GSK3β | |
| Lin et al. | Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer | |
| Huang et al. | Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer | |
| Yang et al. | Nigericin exerts anticancer effects through inhibition of the SRC/STAT3/BCL-2 in osteosarcoma | |
| Li et al. | AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma | |
| Li et al. | Doublecotin-like kinase 1 increases chemoresistance of colorectal cancer cells through the anti-apoptosis pathway | |
| Li et al. | PFKFB4 promotes angiogenesis via IL-6/STAT5A/P-STAT5 signaling in breast cancer | |
| Yang et al. | HSP90 N‐terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2‐driven breast cancer progression | |
| Yan et al. | DZIP1 promotes proliferation, migration, and invasion of oral squamous carcinoma through the GLI1/3 pathway | |
| Li et al. | LncRNA DICER1‐AS1 promotes colorectal cancer progression by activating the MAPK/ERK signaling pathway through sponging miR‐650 | |
| CN114569727B (zh) | 一种治疗癌症的组合物及其应用和药物 | |
| Huang et al. | SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Qi Hailong Inventor after: Sun Zhongjie Inventor after: Liu Defang Inventor after: Wang Xiaofang Inventor after: Li Weiwei Inventor before: Qi Hailong Inventor before: Sun Zhongjie Inventor before: Chen Ligong Inventor before: Xie Huangfan Inventor before: Liu Defang Inventor before: Wang Xiaofang Inventor before: Li Weiwei |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |